StockData

RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3076% below fair value
$5.01+0.18 (+3.73%)

Close on Nov 18, 2026Market cap $208.38MP/E –Yield –

RxSight net income

Net income is the profit left for shareholders after every expense, interest and tax.

RxSight's net income for the twelve months ending Jun 30, 2026 was -$46.95M. For fiscal 2025 it was -$38.94M. The highest annual figure on record is $27.58M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.94M–
FY2024Dec 31, 2024-$27.46M–
FY2023Dec 31, 2023-$48.61M–
FY2022Dec 31, 2022-$66.76M–
FY2021Dec 31, 2021-$48.69M-276.6%
FY2020Dec 31, 2020$27.58M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.10M–
Q1 FY2026Mar 31, 2026-$15.88M–
Q4 FY2025Dec 31, 2025-$9.15M–
Q3 FY2025Sep 30, 2025-$9.82M–
Q2 FY2025Jun 30, 2025-$11.79M–
Q1 FY2025Mar 31, 2025-$8.19M–
Q4 FY2024Dec 31, 2024-$5.94M–
Q3 FY2024Sep 30, 2024-$6.34M–
Q2 FY2024Jun 30, 2024-$6.08M–
Q1 FY2024Mar 31, 2024-$9.10M–
Q4 FY2023Dec 31, 2023-$9.18M–
Q3 FY2023Sep 30, 2023-$12.42M–
Q2 FY2023Jun 30, 2023-$13.80M–
Q1 FY2023Mar 31, 2023-$13.21M–
Q4 FY2022Dec 31, 2022-$15.61M–
Q3 FY2022Sep 30, 2022-$16.82M–
Q2 FY2022Jun 30, 2022-$16.73M–
Q1 FY2022Mar 31, 2022-$17.60M–
Q4 FY2021Dec 31, 2021-$15.73M-159.8%
Q3 FY2021Sep 30, 2021-$12.67M-141.3%
Q2 FY2021Jun 30, 2021-$13.48M–
Q1 FY2021Mar 31, 2021-$6.81M–
Q4 FY2020Dec 31, 2020$26.30M–
Q3 FY2020Sep 30, 2020$30.66M–
Q2 FY2020Jun 30, 2020-$12.88M–
Q1 FY2020Mar 31, 2020-$16.50M–

More RxSight figures

See a number that looks wrong?